IMS 2022 | Factors to consider when sequencing therapies in myeloma
Faith Davies
• 26 Aug 2022
Faith Davies, MBBCh, MRCP, MD, FRCPath, NYU Langone Medical Center, New York, NY, shares some insights into the sequencing of immunotherapies in myeloma and important factors to consider, such as T-cell exhaustion and resistance mechanisms. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
